Logo image of HCWB

HCW BIOLOGICS INC (HCWB) Stock Fundamental Analysis

NASDAQ:HCWB - US40423R2040 - Common Stock

5.55 USD
+2.1 (+60.82%)
Last: 8/25/2025, 8:00:01 PM
5.56 USD
+0.01 (+0.18%)
After Hours: 8/25/2025, 8:00:01 PM
Fundamental Rating

1

Overall HCWB gets a fundamental rating of 1 out of 10. We evaluated HCWB against 547 industry peers in the Biotechnology industry. HCWB has a bad profitability rating. Also its financial health evaluation is rather negative. HCWB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HCWB has reported negative net income.
HCWB had a negative operating cash flow in the past year.
HCWB had negative earnings in each of the past 5 years.
In the past 5 years HCWB always reported negative operating cash flow.
HCWB Yearly Net Income VS EBIT VS OCF VS FCFHCWB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

HCWB's Return On Assets of -93.10% is on the low side compared to the rest of the industry. HCWB is outperformed by 73.49% of its industry peers.
Industry RankSector Rank
ROA -93.1%
ROE N/A
ROIC N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HCWB Yearly ROA, ROE, ROICHCWB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

Looking at the Gross Margin, with a value of 23.92%, HCWB is in the better half of the industry, outperforming 72.76% of the companies in the same industry.
HCWB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HCWB Yearly Profit, Operating, Gross MarginsHCWB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

HCWB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HCWB has more shares outstanding
HCWB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HCWB is higher compared to a year ago.
HCWB Yearly Shares OutstandingHCWB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
HCWB Yearly Total Debt VS Total AssetsHCWB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -9.33, we must say that HCWB is in the distress zone and has some risk of bankruptcy.
HCWB's Altman-Z score of -9.33 is on the low side compared to the rest of the industry. HCWB is outperformed by 70.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.33
ROIC/WACCN/A
WACC9.31%
HCWB Yearly LT Debt VS Equity VS FCFHCWB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

HCWB has a Current Ratio of 0.07. This is a bad value and indicates that HCWB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.07, HCWB is doing worse than 97.07% of the companies in the same industry.
HCWB has a Quick Ratio of 0.07. This is a bad value and indicates that HCWB is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.07, HCWB is not doing good in the industry: 96.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
HCWB Yearly Current Assets VS Current LiabilitesHCWB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for HCWB have decreased strongly by -66.67% in the last year.
The Revenue for HCWB has decreased by -57.71% in the past year. This is quite bad
Measured over the past years, HCWB shows a very negative growth in Revenue. The Revenue has been decreasing by -11.50% on average per year.
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-57.71%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-98.87%

3.2 Future

HCWB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.42% yearly.
Based on estimates for the next years, HCWB will show a very strong growth in Revenue. The Revenue will grow by 141.38% on average per year.
EPS Next Y16.94%
EPS Next 2Y35.37%
EPS Next 3Y22.04%
EPS Next 5Y17.42%
Revenue Next Year368.22%
Revenue Next 2Y89.11%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HCWB Yearly Revenue VS EstimatesHCWB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 2028 2029 2030 200M 400M 600M
HCWB Yearly EPS VS EstimatesHCWB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HCWB. In the last year negative earnings were reported.
Also next year HCWB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HCWB Price Earnings VS Forward Price EarningsHCWB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HCWB Per share dataHCWB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

HCWB's earnings are expected to grow with 22.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.37%
EPS Next 3Y22.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HCWB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HCW BIOLOGICS INC

NASDAQ:HCWB (8/25/2025, 8:00:01 PM)

After market: 5.56 +0.01 (+0.18%)

5.55

+2.1 (+60.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-18 2025-08-18/dmh
Earnings (Next)N/A N/A
Inst Owners1.35%
Inst Owner Change-98.13%
Ins Owners30.09%
Ins Owner Change18.01%
Market Cap11.93M
Analysts82.86
Price Target35.7 (543.24%)
Short Float %5.64%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-70.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)79.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.26
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-28
EYN/A
EPS(NY)-4.69
Fwd EYN/A
FCF(TTM)-6.64
FCFYN/A
OCF(TTM)-6.58
OCFYN/A
SpS0.67
BVpS-3.98
TBVpS-3.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.1%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.92%
FCFM N/A
ROA(3y)-72.93%
ROA(5y)-57.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.65%
Cap/Sales 9.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -9.33
F-Score1
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)665.42%
Cap/Depr(5y)407.44%
Cap/Sales(3y)127.14%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y16.94%
EPS Next 2Y35.37%
EPS Next 3Y22.04%
EPS Next 5Y17.42%
Revenue 1Y (TTM)-57.71%
Revenue growth 3Y-11.5%
Revenue growth 5YN/A
Sales Q2Q%-98.87%
Revenue Next Year368.22%
Revenue Next 2Y89.11%
Revenue Next 3Y-25.99%
Revenue Next 5Y141.38%
EBIT growth 1Y17.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.68%
OCF growth 3YN/A
OCF growth 5YN/A